1
|
Kalonji T, Malembi E, Matela JP, Likafi T, Kinganda-Lusamaki E, Vakaniaki EH, Hoff NA, Aziza A, Muyembe F, Kabamba J, Cooreman T, Nguete B, Witte D, Ayouba A, Fernandez-Nuñez N, Roge S, Peeters M, Merritt S, Ahuka-Mundeke S, Delaporte E, Pukuta E, Mariën J, Bangwen E, Lakin S, Lewis C, Doty JB, Liesenborghs L, Hensley LE, McCollum A, Rimoin AW, Muyembe-Tamfum JJ, Shongo R, Kaba D, Mbala-Kingebeni P. Co-Circulating Monkeypox and Swinepox Viruses, Democratic Republic of the Congo, 2022. Emerg Infect Dis 2024; 30:761-765. [PMID: 38526165 PMCID: PMC10977837 DOI: 10.3201/eid3004.231413] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/26/2024] Open
Abstract
In September 2022, deaths of pigs manifesting pox-like lesions caused by swinepox virus were reported in Tshuapa Province, Democratic Republic of the Congo. Two human mpox cases were found concurrently in the surrounding community. Specific diagnostics and robust sequencing are needed to characterize multiple poxviruses and prevent potential poxvirus transmission.
Collapse
|
2
|
Brooks JT, Reynolds MG, Torrone E, McCollum A, Spicknall IH, Gigante CM, Li Y, Satheshkumar PS, Quilter LAS, Rao AK, O'Shea J, Guagliardo SAJ, Townsend M, Hutson CL. How the Orthodox Features of Orthopoxviruses Led to an Unorthodox Mpox Outbreak: What We've Learned, and What We Still Need to Understand. J Infect Dis 2024; 229:S121-S131. [PMID: 37861379 DOI: 10.1093/infdis/jiad465] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2023] [Revised: 10/13/2023] [Accepted: 10/18/2023] [Indexed: 10/21/2023] Open
Abstract
Orthopoxviruses have repeatedly confounded expectations in terms of the clinical illness they cause and their patterns of spread. Monkeypox virus (MPXV), originally characterized in the late 1950s during outbreaks among captive primates, has been recognized since the 1970s to cause human disease (mpox) in West and Central Africa, where interhuman transmission has largely been associated with nonsexual, close physical contact. In May 2022, a focus of MPXV transmission was detected, spreading among international networks of gay, bisexual, and other men who have sex with men. The outbreak grew in both size and geographic scope, testing the strength of preparedness tools and public health science alike. In this article we consider what was known about mpox before the 2022 outbreak, what we learned about mpox during the outbreak, and what continued research is needed to ensure that the global public health community can detect, and halt further spread of this disease threat.
Collapse
Affiliation(s)
- John T Brooks
- Mpox Multinational Response, US Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Mary G Reynolds
- Mpox Multinational Response, US Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Elizabeth Torrone
- Mpox Multinational Response, US Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Andrea McCollum
- Mpox Multinational Response, US Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Ian H Spicknall
- Mpox Multinational Response, US Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Crystal M Gigante
- Mpox Multinational Response, US Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Yu Li
- Mpox Multinational Response, US Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | | | - Laura A S Quilter
- Mpox Multinational Response, US Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Agam K Rao
- Mpox Multinational Response, US Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Jesse O'Shea
- Mpox Multinational Response, US Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Sarah Anne J Guagliardo
- Mpox Multinational Response, US Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Michael Townsend
- Mpox Multinational Response, US Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Christina L Hutson
- Mpox Multinational Response, US Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| |
Collapse
|
3
|
Meseko C, Adedeji A, Shittu I, Obishakin E, Nanven M, Suleiman L, Okomah D, Tyakaray V, Kolade D, Yinka-Ogunleye A, Muhammad S, Morgan CN, Matheny A, Nakazawa Y, McCollum A, Doty JB. Orthopoxvirus Infections in Rodents, Nigeria, 2018-2019. Emerg Infect Dis 2023; 29:433-434. [PMID: 36692495 PMCID: PMC9881785 DOI: 10.3201/eid2902.221411] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
Abstract
To investigate animal reservoirs of monkeypox virus in Nigeria, we sampled 240 rodents during 2018-2019. Molecular (real-time PCR) and serologic (IgM) evidence indicated orthopoxvirus infections, but presence of monkeypox virus was not confirmed. These results can be used to develop public health interventions to reduce human infection with orthopoxviruses.
Collapse
|
4
|
Thakur KT, Chu V, Hughes C, Kim CY, Fleck-Dardarian S, Barrett K, Matthews E, Balbi A, Bilski A, Chomba M, Lieberman O, Jacobson S, Agarwal S, Roh D, Park S, Ssonko V, Silver W, Vargas W, Geneslaw A, Bell M, Waters B, Rao A, Claassen J, Boehme A, Willey J, Elkind M, Sobieszcyzk M, Zucker J, McCollum A, Sejvar J. Risk Factors for New Neurologic Diagnoses in Hospitalized Patients with COVID-19: A Case-Control Study in New York City. Neurol Clin Pract 2022; 12:e66-e74. [DOI: 10.1212/cpj.0000000000200006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2022] [Accepted: 04/26/2022] [Indexed: 11/15/2022]
Abstract
Abstract:Background/Objective: There have been numerous reports of neurological manifestations identified in hospitalized patients infected with SARS-CoV-2, the virus that causes COVID-19. Here, we identify the spectrum of associated neurological symptoms and diagnoses, define the time course of their development, examine readmission rates and mortality risk post-hospitalization in a multiethnic urban cohort.Methods: We identify the occurrence of new neurological diagnoses among patients with laboratory-confirmed SARS-CoV-2 infection in New York City. A retrospective cohort study was performed of 532 cases (hospitalized patients with new neurological diagnoses within 6 weeks of positive SARS-CoV-2 laboratory results between March 1, 2020 and August 31, 2020). We compare demographic and clinical features of the 532 cases to 532 COVID-19 positive controls without neurological diagnoses in a case-control study with 1 to 1 matching; and examine hospital-related data and outcomes of death and readmission up to 6 months after acute hospitalization in a secondary case-only analysis.Results: Among the 532 cases, the most common new neurological diagnoses included encephalopathy (478, 89.8%), stroke (66, 12.4%), and seizures (38, 7.1%). In the case-control study, cases were more likely than controls to be male (58.6% vs. 52.8%, p=0.05), have baseline neurological comorbidities (36.3% vs. 13.0%, p<0.0001) and be treated in an intensive care unit (ICU) (62.0% vs. 9.6%, p < 0.0001). Of the 394 (74.1%) cases that survived the acute hospitalization, more than half (220/394, 55.8%) were readmitted within 6 months, with a mortality rate of 23.2% during readmission.Conclusion: Many patients hospitalized with SARS-CoV-2 have new neurological diagnoses, with significant morbidity and mortality post-discharge. Further research is needed to define the impact of neurological diagnoses during acute hospitalization on longitudinal post-COVID-19 related symptoms including neurocognitive impairment.
Collapse
|
5
|
Simpson K, Heymann D, Brown CS, Edmunds WJ, Elsgaard J, Fine P, Hochrein H, Hoff NA, Green A, Ihekweazu C, Jones TC, Lule S, Maclennan J, McCollum A, Mühlemann B, Nightingale E, Ogoina D, Ogunleye A, Petersen B, Powell J, Quantick O, Rimoin AW, Ulaeato D, Wapling A. Human monkeypox - After 40 years, an unintended consequence of smallpox eradication. Vaccine 2020; 38:5077-5081. [PMID: 32417140 PMCID: PMC9533855 DOI: 10.1016/j.vaccine.2020.04.062] [Citation(s) in RCA: 171] [Impact Index Per Article: 42.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2020] [Accepted: 04/26/2020] [Indexed: 12/14/2022]
Abstract
Smallpox eradication, coordinated by the WHO and certified 40 years ago, led to the cessation of routine smallpox vaccination in most countries. It is estimated that over 70% of the world's population is no longer protected against smallpox, and through cross-immunity, to closely related orthopox viruses such as monkeypox. Monkeypox is now a re-emerging disease. Monkeypox is endemic in as yet unconfirmed animal reservoirs in sub-Saharan Africa, while its human epidemiology appears to be changing. Monkeypox in small animals imported from Ghana as exotic pets was at the origin of an outbreak of human monkeypox in the USA in 2003. Travellers infected in Nigeria were at the origin of monkeypox cases in the UK in 2018 and 2019, Israel in 2018 and Singapore in2019. Together with sporadic reports of human infections with other orthopox viruses, these facts invite speculation that emergent or re-emergent human monkeypox might fill the epidemiological niche vacated by smallpox. An ad-hoc and unofficial group of interested experts met to consider these issues at Chatham House, London in June 2019, in order to review available data and identify monkeypox-related research gaps. Gaps identified by the experts included:The experts further agreed on the need for a better understanding of the genomic evolution and changing epidemiology of orthopox viruses, the usefulness of in-field genomic diagnostics, and the best disease control strategies, including the possibility of vaccination with new generation non-replicating smallpox vaccines and treatment with recently developed antivirals.
Collapse
Affiliation(s)
- Karl Simpson
- JKS Bioscience Limited, 2 Midanbury Court, 44 Midanbury Lane, Southampton SO18 4HF, UK.
| | - David Heymann
- London School of Hygiene & Tropical Medicine, Keppel St, Bloomsbury, London WC1E 7HT, UK.
| | - Colin S Brown
- Public Health England, Colindale, 61 Colindale Avenue, London NW9 5EQ, UK.
| | - W John Edmunds
- London School of Hygiene & Tropical Medicine, Keppel St, Bloomsbury, London WC1E 7HT, UK.
| | - Jesper Elsgaard
- Bavarian Nordic A/S, Hejreskovvej 10A, DK-3490 Kvistgård, Denmark.
| | - Paul Fine
- London School of Hygiene & Tropical Medicine, Keppel St, Bloomsbury, London WC1E 7HT, UK.
| | | | - Nicole A Hoff
- Fielding School of Public Health, UCLA, 50 Charles E Young Dr S, Los Angeles, CA 90095, United States.
| | - Andrew Green
- Royal Centre of Defence Medicine, Level 2 QEHB, Mindelsohn Way, Edgbaston, Birmingham B15 2WB,UK.
| | - Chikwe Ihekweazu
- Nigeria CDC, Plot 801, Ebitu Ukiwe Street, Jabi, Abuja, Nigeria.
| | - Terry C Jones
- Centre for Pathogen Evolution, Department of Zoology, University of Cambridge, Downing St., Cambridge CB2 3EJ, UK; Institute of Virology, Charité, Universitätsmedizin Charitéplatz 1, 10117 Berlin, Germany.
| | - Swaib Lule
- University College London, Faculty of Population Health Sciences, 30 Guilford Street, London WC1N 1EH, UK.
| | - Jane Maclennan
- Bavarian Nordic GmbH, Fraunhoferstraße 13, 82152 Planegg, Germany.
| | - Andrea McCollum
- Centers for Disease Control and Prevention, 1600 Clifton Rd. NE, CDC, Atlanta, GA 30333, USA.
| | - Barbara Mühlemann
- Centre for Pathogen Evolution, Department of Zoology, University of Cambridge, Downing St., Cambridge CB2 3EJ, UK; Institute of Virology, Charité, Universitätsmedizin Charitéplatz 1, 10117 Berlin, Germany.
| | - Emily Nightingale
- The Forge Veterinary Centre, 93b Head Street, Halstead, Essex CO9 2AZ, UK.
| | - Dimie Ogoina
- Niger Delta University/Niger Delta University Teaching Hospital, Bayelsa, Nigeria
| | - Adesola Ogunleye
- Nigeria CDC, Plot 801, Ebitu Ukiwe Street, Jabi, Abuja, Nigeria.
| | - Brett Petersen
- Centers for Disease Control and Prevention, 1600 Clifton Rd. NE, CDC, Atlanta, GA 30333, USA.
| | - Jacqueline Powell
- Bavarian Nordic Inc, 3025 Carrington Mill Blvd, Morrisville, NC 27560, USA.
| | - Ollie Quantick
- SO1 Public Health and Health Protection, Army Headquarters, Ground Floor, Zone1, Blenheim Bd, Marlborough Lines, Monxton Road, Andover, Hampshire SP11 8HJ, UK.
| | - Anne W Rimoin
- Fielding School of Public Health, UCLA, 50 Charles E Young Dr S, Los Angeles, CA 90095, United States.
| | - David Ulaeato
- CBR Division, Defence Science & Technology Laboratory, Porton Down, Salisbury SP4 0JQ, UK.
| | - Andy Wapling
- Regional Head of Emergency Preparedness, Resilience and Response, NHS England (South West & South East), UK.
| |
Collapse
|
6
|
Yinka-Ogunleye A, Aruna O, Dalhat M, Ogoina D, McCollum A, Disu Y, Mamadu I, Akinpelu A, Ahmad A, Burga J, Ndoreraho A, Nkunzimana E, Manneh L, Mohammed A, Adeoye O, Tom-Aba D, Silenou B, Ipadeola O, Saleh M, Adeyemo A, Nwadiutor I, Aworabhi N, Uke P, John D, Wakama P, Reynolds M, Mauldin MR, Doty J, Wilkins K, Musa J, Khalakdina A, Adedeji A, Mba N, Ojo O, Krause G, Ihekweazu C. Outbreak of human monkeypox in Nigeria in 2017-18: a clinical and epidemiological report. Lancet Infect Dis 2019; 19:872-879. [PMID: 31285143 PMCID: PMC9628943 DOI: 10.1016/s1473-3099(19)30294-4] [Citation(s) in RCA: 404] [Impact Index Per Article: 80.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/09/2018] [Revised: 03/25/2019] [Accepted: 04/05/2019] [Indexed: 01/02/2023]
Abstract
BACKGROUND In September, 2017, human monkeypox re-emerged in Nigeria, 39 years after the last reported case. We aimed to describe the clinical and epidemiological features of the 2017-18 human monkeypox outbreak in Nigeria. METHODS We reviewed the epidemiological and clinical characteristics of cases of human monkeypox that occurred between Sept 22, 2017, and Sept 16, 2018. Data were collected with a standardised case investigation form, with a case definition of human monkeypox that was based on previously established guidelines. Diagnosis was confirmed by viral identification with real-time PCR and by detection of positive anti-orthopoxvirus IgM antibodies. Whole-genome sequencing was done for seven cases. Haplotype analysis results, genetic distance data, and epidemiological data were used to infer a likely series of events for potential human-to-human transmission of the west African clade of monkeypox virus. FINDINGS 122 confirmed or probable cases of human monkeypox were recorded in 17 states, including seven deaths (case fatality rate 6%). People infected with monkeypox virus were aged between 2 days and 50 years (median 29 years [IQR 14]), and 84 (69%) were male. All 122 patients had vesiculopustular rash, and fever, pruritus, headache, and lymphadenopathy were also common. The rash affected all parts of the body, with the face being most affected. The distribution of cases and contacts suggested both primary zoonotic and secondary human-to-human transmission. Two cases of health-care-associated infection were recorded. Genomic analysis suggested multiple introductions of the virus and a single introduction along with human-to-human transmission in a prison facility. INTERPRETATION This study describes the largest documented human outbreak of the west African clade of the monkeypox virus. Our results suggest endemicity of monkeypox virus in Nigeria, with some evidence of human-to-human transmission. Further studies are necessary to explore animal reservoirs and risk factors for transmission of the virus in Nigeria. FUNDING None.
Collapse
Affiliation(s)
| | - Olusola Aruna
- Nigeria Centre for Disease Control, Abuja, Nigeria; International Health Regulations Strengthening Programme in Nigeria, Public Health England, Abuja, Nigeria
| | | | - Dimie Ogoina
- Niger Delta University Teaching Hospital, Niger Delta University, Yenagoa, Nigeria
| | - Andrea McCollum
- Poxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, US Centers for Disease Control and Prevention, Atlanta, GA, USA
| | - Yahyah Disu
- Nigeria Centre for Disease Control, Abuja, Nigeria
| | | | | | - Adama Ahmad
- Nigeria Centre for Disease Control, Abuja, Nigeria
| | - Joel Burga
- Nigeria Centre for Disease Control, Abuja, Nigeria
| | - Adolphe Ndoreraho
- Nigeria Field Epidemiology and Laboratory Training Programme, Abuja, Nigeria
| | - Edouard Nkunzimana
- Nigeria Field Epidemiology and Laboratory Training Programme, Abuja, Nigeria
| | - Lamin Manneh
- Nigeria Field Epidemiology and Laboratory Training Programme, Abuja, Nigeria
| | | | | | - Daniel Tom-Aba
- Helmholtz Centre for Infection Research, Braunschweig, Germany; German Centre for Infection Research, Braunschweig, Germany
| | - Bernard Silenou
- Helmholtz Centre for Infection Research, Braunschweig, Germany; German Centre for Infection Research, Braunschweig, Germany
| | - Oladipupo Ipadeola
- Poxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, US Centers for Disease Control and Prevention, Atlanta, GA, USA
| | - Muhammad Saleh
- Poxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, US Centers for Disease Control and Prevention, Atlanta, GA, USA
| | | | | | | | - Patience Uke
- Cross State Ministry of Health, Calabar, Nigeria
| | - Doris John
- Department of Health, Federal Capital Territory, Abuja, Nigeria
| | - Paul Wakama
- Nigeria Prison Services, Port Harcourt, Rivers State, Nigeria
| | - Mary Reynolds
- Poxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, US Centers for Disease Control and Prevention, Atlanta, GA, USA
| | - Matthew R Mauldin
- Poxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, US Centers for Disease Control and Prevention, Atlanta, GA, USA
| | - Jeffrey Doty
- Poxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, US Centers for Disease Control and Prevention, Atlanta, GA, USA
| | - Kimberly Wilkins
- Poxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, US Centers for Disease Control and Prevention, Atlanta, GA, USA
| | - Joy Musa
- University Of Maryland, Abuja, Nigeria
| | | | | | - Nwando Mba
- Nigeria Centre for Disease Control, Abuja, Nigeria
| | - Olubunmi Ojo
- Nigeria Centre for Disease Control, Abuja, Nigeria
| | - Gerard Krause
- Helmholtz Centre for Infection Research, Braunschweig, Germany; German Centre for Infection Research, Braunschweig, Germany
| | | |
Collapse
|
7
|
Yinka-Ogunleye A, Aruna O, Ogoina D, Aworabhi N, Eteng W, Badaru S, Mohammed A, Agenyi J, Etebu EN, Numbere TW, Ndoreraho A, Nkunzimana E, Disu Y, Dalhat M, Nguku P, Mohammed A, Saleh M, McCollum A, Wilkins K, Faye O, Sall A, Happi C, Mba N, Ojo O, Ihekweazu C. Reemergence of Human Monkeypox in Nigeria, 2017. Emerg Infect Dis 2018; 24:1149-1151. [PMID: 29619921 PMCID: PMC6004876 DOI: 10.3201/eid2406.180017] [Citation(s) in RCA: 116] [Impact Index Per Article: 19.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Abstract
In Nigeria, before 2017 the most recent case of human monkeypox had been reported in 1978. By mid-November 2017, a large outbreak caused by the West African clade resulted in 146 suspected cases and 42 laboratory-confirmed cases from 14 states. Although the source is unknown, multiple sources are suspected.
Collapse
|
8
|
Carrel M, Patel J, Taylor SM, Janko M, Mwandagalirwa MK, Tshefu AK, Escalante AA, McCollum A, Alam MT, Udhayakumar V, Meshnick S, Emch M. The geography of malaria genetics in the Democratic Republic of Congo: A complex and fragmented landscape. Soc Sci Med 2014; 133:233-41. [PMID: 25459204 DOI: 10.1016/j.socscimed.2014.10.037] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2014] [Revised: 08/27/2014] [Accepted: 10/17/2014] [Indexed: 11/28/2022]
Abstract
Understanding how malaria parasites move between populations is important, particularly given the potential for malaria to be reintroduced into areas where it was previously eliminated. We examine the distribution of malaria genetics across seven sites within the Democratic Republic of Congo (DRC) and two nearby countries, Ghana and Kenya, in order to understand how the relatedness of malaria parasites varies across space, and whether there are barriers to the flow of malaria parasites within the DRC or across borders. Parasite DNA was retrieved from dried blood spots from 7 Demographic and Health Survey sample clusters in the DRC. Malaria genetic characteristics of parasites from Ghana and Kenya were also obtained. For each of 9 geographic sites (7 DRC, 1 Ghana and 1 Kenya), a pair-wise RST statistic was calculated, indicating the genetic distance between malaria parasites found in those locations. Mapping genetics across the spatial extent of the study area indicates a complex genetic landscape, where relatedness between two proximal sites may be relatively high (RST > 0.64) or low (RST < 0.05), and where distal sites also exhibit both high and low genetic similarity. Mantel's tests suggest that malaria genetics differ as geographic distances increase. Principal Coordinate Analysis suggests that genetically related samples are not co-located. Barrier analysis reveals no significant barriers to gene flow between locations. Malaria genetics in the DRC have a complex and fragmented landscape. Limited exchange of genes across space is reflected in greater genetic distance between malaria parasites isolated at greater geographic distances. There is, however, evidence for close genetic ties between distally located sample locations, indicating that movement of malaria parasites and flow of genes is being driven by factors other than distance decay. This research demonstrates the contributions that spatial disease ecology and landscape genetics can make to understanding the evolutionary dynamics of infectious diseases.
Collapse
Affiliation(s)
- Margaret Carrel
- Department of Geographical & Sustainability Sciences, University of Iowa, Iowa City, IA, USA.
| | - Jaymin Patel
- Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina- Chapel Hill Chapel Hill, NC, USA
| | - Steve M Taylor
- Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina- Chapel Hill Chapel Hill, NC, USA; Division of Infectious Diseases and International Health, Duke University Medical Center, Durham, NC, USA; Duke Global Health Institute, Durham, NC, USA
| | - Mark Janko
- Department of Geography, University of North Carolina-Chapel Hill, Chapel Hill, NC, USA
| | - Melchior Kashamuka Mwandagalirwa
- Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina- Chapel Hill Chapel Hill, NC, USA
| | - Antoinette K Tshefu
- Ecole de Sante Publique, Faculte de Medecine, University of Kinshasa, Kinshasa, Democratic Republic of the Congo
| | - Ananias A Escalante
- Center for Evolutionary Medicine & Informatics, The Biodesign Institute, Arizona State University, Tempe, AZ, USA
| | - Andrea McCollum
- Malaria Branch, Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA
| | - Md Tauqeer Alam
- Malaria Branch, Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA
| | - Venkatachalam Udhayakumar
- Malaria Branch, Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA
| | - Steven Meshnick
- Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina- Chapel Hill Chapel Hill, NC, USA
| | - Michael Emch
- Department of Geography, University of North Carolina-Chapel Hill, Chapel Hill, NC, USA
| |
Collapse
|
9
|
McCollum A, Nakazawa Y, Ndongala GM, Pukuta E, Karhemere S, Lushima RS, Ilunga BK, Kabamba J, Li Y, Damon I, Carroll D, Reynolds M, Malekani J, Tamfum JJM. Human monkeypox in the Kivus, a conflict region of The Democratic Republic of the Congo. Int J Infect Dis 2014. [DOI: 10.1016/j.ijid.2014.03.820] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
10
|
Reynolds M, Malekani J, Damon I, Monroe B, Kabamba J, Lushima RS, Nguete B, Karhemere S, Pukuta E, Tack D, McCollum A, Bass J, Wemakoy O. Training health workers for enhanced monkeypox surveillance, Democratic Republic of the Congo. Int J Infect Dis 2014. [DOI: 10.1016/j.ijid.2014.03.990] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
11
|
Hays JL, Kim G, Mariani J, Murphy RF, Angelos M, McCollum A, Lu J, Widemann BC, Lee J, Kohn EC. Sequence specific effects on DNA and cell damage with the PARP inhibitor olaparib (AZD2281) and carboplatin. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.5025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
12
|
Agarwala AK, Hanna N, McCollum A, Bechar N, DiMaio M, Yu M, Tong Y, Becerra CR, Choy H. Preoperative cetuximab and radiation (XRT) for patients (pts) with surgically resectable esophageal and gastroesophageal junction (GEJ) carcinomas: A pilot study from the Hoosier Oncology Group and the University of Texas Southwestern. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.4557] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4557 Background: Pre-operative chemoradiotherapy (CRT) followed by surgical resection is a standard treatment option for pts with resectable esophageal or GE junction (GEJ) carcinomas (CA). Cetuximab, when combined with XRT is effective treatment for locally advanced cancers of the head and neck. We conducted this study to evaluate this regimen in pts with esophageal and GEJ CA. Methods: This is a single arm, open label pilot study combining cetuximab with XRT for pts with resectable esophageal and GEJ CA. The primary objective is to determine the pathologic complete response rate (pCR) (null hypothesis: p=0.20; alternative hypothesis: p=0.35) and determine the feasibility and toxicity of this regimen when given prior to esophagectomy. Key eligibility criteria are: squamous cell (SC)or adenoCA of the esophagus or GEJ, ECOG PS 0–2, clinical stage II -IVa, and eligible for esophagectomy. Pts received a loading dose of cetuximab at 400mg/m2 2 weeks prior to XRT, then weekly at 250 mg/m2 starting one week prior to XRT until completion of 50.4 Gy XRT. After satisfactory recovery, pts had esophagectomy. Results: Patient characteristics (n=40): median age 65 years (range, 54–82); 92% male; PS 0/1 63%/32%; esophageal/GEJ 65%/35%; adenoCA/SC 78%/22%; 36 pts have completed cetuximab and radiation and 26 pts have undergone esophagectomy. Of the 26 pts that have undergone esophagectomy, 13 obtained a pCR. 5/13 SC had pCR and 8/13 adenoCA had pCR. 10 pts did not undergo surgery for various reasons including disease progression (n=7), AE unrelated to treatment (n=2), and personal decision to forgo esophagectomy (n=1). 4 patients are still completing cetuximab/XRT. The most common G3 adverse event was rash (56%). Other G3 toxicities were infrequent and included dysphagia (6%), infection (6%), and GI bleed (3%). There have been no treatment or surgery related deaths. Conclusions: Cetuximab and XRT results in pCR's in pts with esophageal and GEJ CA (rate of pCR 13/36), including patients with either SC or adenoCA histologies. G3/4 toxicities, including dysphagia were generally uncommon. Further study of this combination prior to esophagectomy is warranted. [Table: see text]
Collapse
Affiliation(s)
- A. K. Agarwala
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Baylor Sammons Cancer Center, Dallas, TX; Community Oncology Center, Kokomo, IN; UT Southwestern Medical Center at Dallas, Dallas, TX; Indiana University School of Medicine, Indianapolis, IN
| | - N. Hanna
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Baylor Sammons Cancer Center, Dallas, TX; Community Oncology Center, Kokomo, IN; UT Southwestern Medical Center at Dallas, Dallas, TX; Indiana University School of Medicine, Indianapolis, IN
| | - A. McCollum
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Baylor Sammons Cancer Center, Dallas, TX; Community Oncology Center, Kokomo, IN; UT Southwestern Medical Center at Dallas, Dallas, TX; Indiana University School of Medicine, Indianapolis, IN
| | - N. Bechar
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Baylor Sammons Cancer Center, Dallas, TX; Community Oncology Center, Kokomo, IN; UT Southwestern Medical Center at Dallas, Dallas, TX; Indiana University School of Medicine, Indianapolis, IN
| | - M. DiMaio
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Baylor Sammons Cancer Center, Dallas, TX; Community Oncology Center, Kokomo, IN; UT Southwestern Medical Center at Dallas, Dallas, TX; Indiana University School of Medicine, Indianapolis, IN
| | - M. Yu
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Baylor Sammons Cancer Center, Dallas, TX; Community Oncology Center, Kokomo, IN; UT Southwestern Medical Center at Dallas, Dallas, TX; Indiana University School of Medicine, Indianapolis, IN
| | - Y. Tong
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Baylor Sammons Cancer Center, Dallas, TX; Community Oncology Center, Kokomo, IN; UT Southwestern Medical Center at Dallas, Dallas, TX; Indiana University School of Medicine, Indianapolis, IN
| | - C. R. Becerra
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Baylor Sammons Cancer Center, Dallas, TX; Community Oncology Center, Kokomo, IN; UT Southwestern Medical Center at Dallas, Dallas, TX; Indiana University School of Medicine, Indianapolis, IN
| | - H. Choy
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Baylor Sammons Cancer Center, Dallas, TX; Community Oncology Center, Kokomo, IN; UT Southwestern Medical Center at Dallas, Dallas, TX; Indiana University School of Medicine, Indianapolis, IN
| |
Collapse
|
13
|
Hamel MJ, Poe A, Bloland P, McCollum A, Zhou Z, Shi YP, Ouma P, Otieno K, Vulule J, Escalante A, Udhayakumar V, Slutsker L. Dihydrofolate reductase I164L mutations in Plasmodium falciparum isolates: clinical outcome of 14 Kenyan adults infected with parasites harbouring the I164L mutation. Trans R Soc Trop Med Hyg 2008; 102:338-45. [DOI: 10.1016/j.trstmh.2008.01.018] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2007] [Revised: 01/24/2008] [Accepted: 01/24/2008] [Indexed: 11/25/2022] Open
|
14
|
Hunt von Herbing I, McCollum A, Geubtner J. 2.4. Energy metabolism and physiological variability in developing fishes. Comp Biochem Physiol A Mol Integr Physiol 2007. [DOI: 10.1016/j.cbpa.2007.06.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
15
|
Yu C, Friday BB, Lai JP, McCollum A, Atadja P, Roberts LR, Adjei AA. Abrogation of MAPK and Akt Signaling by AEE788 Synergistically Potentiates Histone Deacetylase Inhibitor-Induced Apoptosis through Reactive Oxygen Species Generation. Clin Cancer Res 2007; 13:1140-8. [PMID: 17317822 DOI: 10.1158/1078-0432.ccr-06-1751] [Citation(s) in RCA: 65] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
PURPOSE To evaluate the effects of combining the multiple receptor tyrosine kinase inhibitor AEE788 and histone deacetylase (HDAC) inhibitors on cytotoxicity in a broad spectrum of cancer cell lines, including cisplatin-resistant ovarian adenocarcinoma cells. EXPERIMENTAL DESIGN Multiple cancer cell lines were treated in vitro using AEE788 and HDAC inhibitors (LBH589, LAQ824, and trichostatin A), either alone or in combination. Effects on cytotoxicity were determined by growth and morphologic assays. Effects of the combination on cell signaling pathways were determined by Western blotting, and the results were confirmed using pathway-specific inhibitors and transfection of constitutively active proteins. RESULTS Cell treatment with AEE788 and HDAC inhibitors (LBH589, LAQ824, and trichostatin A) in combination resulted in synergistic induction of apoptosis in non-small cell lung cancer (MV522, A549), ovarian cancer (SKOV-3), and leukemia (K562, Jurkat, and ML-1) cells and in OV202hp cisplatin-resistant human ovarian cancer cells. AEE788 alone or in combination with LBH589 inactivated mitogen-activated protein kinase (MAPK) and Akt cascades. Inhibition of either MAPK and/or Akt enhanced LBH589-induced apoptosis. In contrast, constitutively active MAPK or Akt attenuated LBH589 or LBH589 + AEE788-induced apoptosis. Increased apoptosis was correlated with enhanced reactive oxygen species (ROS) generation. The free radical scavenger N-acetyl-l-cysteine not only substantially suppressed the ROS accumulation but also blocked the induction of apoptosis mediated by cotreatment with AEE788 and LBH589. CONCLUSION Collectively, these results show that MAPK and Akt inactivation along with ROS generation contribute to the synergistic cytotoxicity of the combination of AEE788 and HDAC inhibitors in a variety of human cancer cell types. This combination regimen warrants further preclinical and possible clinical study for a broad spectrum of cancers.
Collapse
Affiliation(s)
- Chunrong Yu
- Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA
| | | | | | | | | | | | | |
Collapse
|
16
|
Erlichman C, Toft D, Reid J, Goetz M, Ames M, Mandrekar S, Ajei A, McCollum A, Ivy P. A phase I trial of 17-allylamino-geldanamycin (17AAG) in patients with advanced cancer. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.3030] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- C. Erlichman
- Mayo Clinic in Rochester, Rochester, MN; National Cancer Institute/NIH, Rockville, MD
| | - D. Toft
- Mayo Clinic in Rochester, Rochester, MN; National Cancer Institute/NIH, Rockville, MD
| | - J. Reid
- Mayo Clinic in Rochester, Rochester, MN; National Cancer Institute/NIH, Rockville, MD
| | - M. Goetz
- Mayo Clinic in Rochester, Rochester, MN; National Cancer Institute/NIH, Rockville, MD
| | - M. Ames
- Mayo Clinic in Rochester, Rochester, MN; National Cancer Institute/NIH, Rockville, MD
| | - S. Mandrekar
- Mayo Clinic in Rochester, Rochester, MN; National Cancer Institute/NIH, Rockville, MD
| | - A. Ajei
- Mayo Clinic in Rochester, Rochester, MN; National Cancer Institute/NIH, Rockville, MD
| | - A. McCollum
- Mayo Clinic in Rochester, Rochester, MN; National Cancer Institute/NIH, Rockville, MD
| | - P. Ivy
- Mayo Clinic in Rochester, Rochester, MN; National Cancer Institute/NIH, Rockville, MD
| |
Collapse
|
17
|
Mitchell T, Plonczynski M, McCollum A, Hardy CL, Safaya S, Steinberg MH. Gene Expression Profiling during Erythroid Differentiation of K562 Cells. Blood Cells Mol Dis 2001; 27:309-19. [PMID: 11358393 DOI: 10.1006/bcmd.2000.0377] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
We studied the temporal changes in gene expression in K562 cells at intervals from 2 to 48 h following induction using differential display polymerase chain reaction and gene expression arrays. More than 110 cDNA fragments representing 86 unique mRNAs were either up- or downregulated during erythroid differentiation. Sixty-one of the differentially expressed cDNA fragments had more than 95% homology to known GenBank sequences; 21 represented cDNA sequences with only dbEST or high-throughput gene-screening database matches. Four fragments had no database matches. Using gene expression arrays, 73 differentially expressed genes were observed. Unique expressed sequence tags (ESTs) were used to "clone" two novel genes from available databases and their tissue expression was examined. Erythroid maturation in induced K562 cells is associated with differential expression of many genes. Some differentially expressed clones were transcription factors and 25 expressed fragments with open reading frames were found whose function remains unknown.
Collapse
Affiliation(s)
- T Mitchell
- G.V. (Sonny) Montgomery Department of Veterans Affairs Medical Center, University of Mississippi School of Medicine, Jackson, Mississippi 39216, USA
| | | | | | | | | | | |
Collapse
|
18
|
Adam M, Chew M, Wasserman S, McCollum A, McDonald RE, Mossoba MM. Determination of trans
fatty acids in hydrogenated vegetable oils by attenuated total reflection infrared spectroscopy: Two limited collaborative studies. J AM OIL CHEM SOC 1998. [DOI: 10.1007/s11746-998-0052-5] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Affiliation(s)
- M. Adam
- Lipton; Baltimore Maryland 21229
| | - M. Chew
- Lipton; Baltimore Maryland 21229
| | | | | | - R. E. McDonald
- Food and Drug Administration; National Center for Food Safety and Technology; Summit-Argo Illinois 60501
| | - M. M. Mossoba
- the Food and Drug Administration (HFS-717); Center for Food Safety and Applied Nutrition; Washington DC 20204
| |
Collapse
|